Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials

• Main Authors: David F Archer, ProfMD (Author), Ruth B Merkatz, PhD (Author), Luis Bahamondes, ProfMD (Author), Carolyn L Westhoff, ProfMD (Author), Philip Darney, ProfMD (Author), Dan Apter, MD (Author), Jeffrey T Jensen, ProfMD (Author), Vivian Brache, BS (Author), Anita L Nelson, ProfMD (Author), Erika Banks, ProfMD (Author), György Bártfai, ProfMD (Author), David J Portman, MD (Author), Marlena Plagianos, MS (Author), Clint Dart, MS (Author), Narender Kumar, PhD (Author), George W Creasy, MD (Author), Regine Sitruk-Ware, MD (Author), Diana L Blithe, PhD (Author)
• Format: Book
• Published: Elsevier, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0·15 mg segesterone acetate and 0·013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive vaginal system and return to menses or pregnancy after use. M...